Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0NRWPL
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
ADCT-212
|
|||||
| Synonyms |
ADCT212; ADCT 212
Click to Show/Hide
|
|||||
| Organization |
ADC Therapeutics SA
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 2 Indication(s)
Hormone refractory prostate cancer [ICD11:2C82]
Clinical candidate
Prostate cancer [ICD11:2C82]
Clinical candidate
|
|||||
| Drug-to-Antibody Ratio |
1.8
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Prostate-specific antigen (KLK3)
|
Antigen Info | ||||
| Payload Name |
SG2000
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Vali-Ala cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Site-specifically conjugated using GlycoConnect technology to PL1801.
|
|||||
| Combination Type |
PL1801
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.